Connor, Clark & Lunn Investment Management Ltd. Amylyx Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,199,691 shares of AMLX stock, worth $6.14 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,199,691
Previous 1,263,353
5.04%
Holding current value
$6.14 Million
Previous $4.76 Million
10.84%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding AMLX
# of Institutions
150Shares Held
72.6MCall Options Held
148KPut Options Held
98.7K-
Perceptive Advisors LLC New York, NY7.87MShares$40.3 Million1.17% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$30.4 Million5.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.7MShares$29.2 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.12MShares$21.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.08MShares$15.8 Million0.01% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $300M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...